Overview

A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
In this study several doses of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of patients with Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc